UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
|
|
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices, and Zip Code)
Registrant’s Telephone Number, Including Area Code
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
|
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On August 20, 2020, EyePoint Pharmaceuticals, Inc. (the “Company”) issued a press release announcing a Memorandum of Understanding (“MOU”) between the Company and Ocumension Therapeutics (“Ocumension”), pursuant to which the Company received a one-time $9.5 million payment from Ocumension as consideration for the expansion of the territories included in the Company’s license agreements with Ocumension. Such payment also constitutes a full and final prepayment of all remaining development, regulatory and sales milestone payments under the Company’s license agreements with Ocumension. Further, pursuant to its existing debt facility with CRG Servicing LLC (“CRG”), the Company received CRG’s consent to the Company’s execution and delivery of the MOU. The Company also granted to CRG the right to designate a representative of CRG to attend meetings of the Company’s Board of Directors as a non-voting observer. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release of EyePoint Pharmaceuticals, Inc., dated August 20, 2020 |
|
104 |
|
Cover Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
EyePoint Pharmaceuticals, Inc. |
||
|
|
|
|||
|
Date: August 20, 2020 |
|
By: |
|
/s/ Nancy Lurker |
|
|
|
Name: |
|
Nancy Lurker |
|
|
|
Title |
|
President and Chief Executive Officer |